Inhibikase Therapeutics, Inc. (IKT)
SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its 10-Q for the period ended Jun 30, 2026, Inhibikase Therapeutics, Inc. reported revenue of $0, net income of -$19.6M, and total assets of $163.6M. Every figure below is taken directly from Inhibikase Therapeutics, Inc.'s SEC filings: each links to the source document on EDGAR.
Revenue trend
Revenue · FY2020–FY2024 · as reported
- FY2020 revenue
- $698,468
- FY2024 revenue
- $0
Revenue and net income by fiscal year
As reported in each year’s annual filing · USD
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY2025 | — | -$48.3M |
| FY2024 | $0 | -$27.5M |
| FY2023 | $260,501 | -$19.0M |
| FY2022 | $123,440 | -$18.1M |
| FY2021 | $3.1M | -$14.8M |
| FY2020 | $698,468 | -$2.8M |
Recent SEC filings
Filed by the registrant · newest first · insider forms and holder schedules not included
| Form | Filed | Source |
|---|---|---|
| 8-K | Oct 20, 2026 | on EDGAR ↗ |
| 8-K | Sep 8, 2026 | on EDGAR ↗ |
| 8-K | Aug 26, 2026 | on EDGAR ↗ |
| 8-K | Aug 11, 2026 | on EDGAR ↗ |
| 10-Q | Aug 11, 2026 | on EDGAR ↗ |
| 8-K | Jul 29, 2026 | on EDGAR ↗ |
| 8-K | Jul 23, 2026 | on EDGAR ↗ |
| 8-K | Jul 14, 2026 | on EDGAR ↗ |
| 8-K | Jun 29, 2026 | on EDGAR ↗ |
| 8-K | May 12, 2026 | on EDGAR ↗ |
Balance Sheet
as of Jun 30, 2026 · 10-Q
Income Statement
10-Q (quarterly) · period ended Jun 30, 2026
Per Share & Cash Flow
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | $-0.11 | Earnings | source ↗ |
| EPS (basic) | $-0.11 | Earnings | source ↗ |
| Shares Outstanding | 139.5M | Entity | source ↗ |
| Cash from Operations | -$12.4M | Net | source ↗ |
| Cash from Financing | -$14,489 | Net | source ↗ |
| Cash from Investing | -$5.9M | Net | source ↗ |
Insider activity
Form 4 open-market activity, last 180 days
No open-market Form 4 transactions filed in the last 180 days.
Restatement history
Point-in-time6 of 149 annual fact-keys were materially restated between filings: what Inhibikase Therapeutics, Inc. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
Deeper fundamentals
A free API key reaches IKT’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- These fundamentals, as filed
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/IKT
MCP tool:
get_sec_fundamentals ticker=IKT - The same figures as they were known on any past date
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/IKT/as-of/YYYY-MM-DD
MCP tool:
get_asof_fundamentals ticker=IKT as_of=YYYY-MM-DD - Fiscal-year trajectory: revenue, margins, free cash flow
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/fundamentals/IKT/history
MCP tool:
get_fundamentals_history ticker=IKT - Leverage, liquidity, margin and return ratios
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/financial-health/IKT
MCP tool:
get_financial_health ticker=IKT
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.